We thank Pomara et al for their interest and favorable comments, and we wish to address several points that they raised in response to our article, 'High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. ' Pomara et al suggest that the 40-fold selectivity of tadalafil for PDE5 over PDE11A4 may not be sufficient to avoid crossreactivity in patients. They point to the reported 41-fold selectivity of sildenafil for PDE5 over PDE1, which they say may not be sufficient since sildenafil effects on PDE1 could explain the vasodilation, flushing and tachycardia that have been reported for sildenafil. However, since vasodilation and other hemodynamic effects such as flushing are common side-effects of all PDE5 inhibitors, 1-3 they are more likely to be PDE5-specific effects than PDE1-specific effects. We are not aware of confirmed clinical reports showing that any of the approved PDE5 inhibitors causes significant tachycardia when used as directed. We agree that a 40-fold selectivity of tadalafil for PDE5 over PDE11A4 does not completely exclude the possibility of crossreaction, but it reduces the likelihood of such an effect when compared with the five-fold tadalafil selectivity reported for the shortest isoform, PDE11A1. 4 We agree with Pomara et al that the potency of tadalafil for inhibiting the other three PDE11 variants (PDE11A1-11A3) needs to be evaluated, in a head-to-head manner with PDE11A4. However, we caution against drawing conclusions about the possible side-effects based solely on distribution of PDE11A mRNA transcripts. The presence of all four PDE11A variants in humans and their tissue localizations has not yet been reported at the protein level. Poor correlation of mRNA and actual protein levels of many enzymes is commonplace. We point out again that PDE11A4 has the most extensive domain structure in the PDE11A family, and would be predicted to have the most potential for regulation.
The studies referred to by Pomara et al detailing a tadalafil effect on sperm motility in men with preexisting fertility problems are interesting, and emphasize the need for further investigations into PDE11 function and distribution. We are grateful to Pomara et al for their suggestions and criticisms.
